BACE1 levels are increased in plasma of Alzheimer's disease patients compared with matched cognitively healthy controls

Author(s)

Manzine, Patricia Regina ; Souza, Matheus da Silva ; Cominetti, Marcia Regina

• Document type: Journal article
• Source: Personalized Medicine; v. 13, n. 6, p. 531-540, NOV 2016.
• Web of Science Citations: 1

Abstract

Aim: BACE1 is the secretase that acts in A beta production in Alzheimer's disease (AD). Materials \& methods: We investigated mRNA expression in total blood and the levels of plasma protein BACE1 in AD patients compared with cognitively healthy subjects. Probable AD (n = 47) and non-AD control group (n = 32) were evaluated for mRNA expression for BACE1 using reverse transcription-qPCR. A subsample of n = 21 AD and n = 20 non-AD had plasma BACE1 levels analyzed, using ELISA. Results: No differences were found on BACE1 mRNA between groups. However, higher levels of BACE1 were detected in plasma of AD patients. Discussion: Blood-based diagnostic tools are desired to improve AD diagnosis. BACE1 plasma levels could provide an additional diagnostic tool for AD in association with neuropsychological tests. (AU)

• FAPESP's process: 14/06580-1 - Gene expression analysis of BACE1 in patients with Alzheimer's Disease
• Grantee: Matheus da Silva Souza
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• FAPESP's process: 13/06879-4 - Blood biomarkers for Alzheimer's Disease: evaluation of ADAM10 gene expression and microRNAs
• Grantee: Márcia Regina Cominetti
• Support Opportunities: Regular Research Grants
• FAPESP's process: 12/08654-7 - Blood biomarkers for Alzheimer's Disease: evaluation of ADAM10 gene expression and micro-RNAs
• Grantee: Patricia Regina Manzine Moralles
• Support Opportunities: Scholarships in Brazil - Doctorate